Long-Term Safety and Disease Control With Ruxolitinib Cream in Patients With More Severe Atopic Dermatitis: Pooled Results From Two Phase 3 Studies

Main Article Content

Eric Simpson
Leon Kircik
Andrew Blauvelt
Michael Kuligowski
May Venturanza
Kang Sun
Lawrence Eichenfeld

Keywords

safety, ruxolitinib, atopic dermatitis, phase 3 study

Abstract

N/A

References

1. Langan SM, et al. Lancet. 2020;396(10247):345-360.

2. Chopra R, et al. Br J Dermatol. 2017;177(5):1316-1321.

3. Vakharia PP, et al. Br J Dermatol. 2018;178(4):925-930.

4. Gooderham MJ, et al. J Cutan Med Surg. 2018;22(suppl 1):10S-16S.

5. Eichenfield LF, et al. J Am Acad Dermatol. 2014;70(2):338-351.

6. Simpson EL, et al. J Am Acad Dermatol. 2017;77(4):623-633.

7. Papp K, et al. J Am Acad Dermatol. 2021;85(4):863-872.

8. Simpson EL, et al. N Engl J Med. 2016;375(24):2335-2348.

9. Simpson EL, et al. Br J Dermatol. 2020;183(2):242-255.

10. Guttman-Yassky E, et al. J Allergy Clin Immunol. 2020;145(3):877-884.

11. Silverberg JI, et al. JAMA Dermatol. 2020;156(8):863-873

Most read articles by the same author(s)

<< < 2 3 4 5 6 7 8 9 10 > >>